It is widely accepted that the absorbance peak of amniotic fluid at 450 urn represents unconjugated bilirubin (1). In uncomplicated pregnancies, as the normal gestation progresses and the fetal liver matures, the peak of bilirubin absorbance at 450 nm becomes smaller, disappearing completely from samples collected at the 36th week (2). Thus, the absorbance of bilirubin gives a good forecast of fetal maturity at any given period of gestation (1.2). In pregnancies complicated by Rhesus-factor incompatibility the increase in amniotic fluid bilirubin content was found to correlate with the severity of the hemolytic disease of the newborn (3). Measurement of amniotic fluid bilirubin content by the height of the light-absorption peak at 450 nm is therefore an established procedure for the assessment of the Rhesus-isoimmunized pregnancy, and the criteria estab- 'Address all correspondence to this author, at the Dept. of Clin.
whether or not low concentrationsof bilirubin(<1.6 &mol/L) are present. Thus the effect on absorbance evidentlyis not ascribable to supersaturation and formation of a colloidal sol of bitirubin particles. This direct interference of glucocorticoids with the spectrophotometry of bilirubin in amniotic fluid prompts cautious interpretation of such data as an index to the severityofhemolytic disease of the fetus, specifically in cases of Rhesus-isoimmunization that are being treated with glucocorticoids.
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hemolysis and to accelerate fetal lung maturity (7). Several reports have indeed shown that administration of glucocorticoids to Rhesus-sensitized pregnant women produces a decline in the absorbance value of the amniotic fluid at 450 nm (7) (8) (9) . However, an abrupt increase in absorbance was notedimmediately after the steroid injections were stopped (7) , and the glucocorticoids produced only minimal, if any, changes in the lecithin/sphingomyelin ratio of amniotic fluid, suggesting that neither the hemolytic disease nor fetal maturity was actually improved by therapy with steroid (8).
In view of the possibility that a steroid-induced decrease in absorbance at 450 nm does not necessarily reflect a true biological effect on bilirubin content, we investigated the direct in vitro effect of glucocorticoids on the spectrophotometric determination of bilirubin in amniotic fluid. Our results show that steroids directly decrease the absorbance peak at 450 nrn in vitro, suggesting that direct spectrophotometry of bilirubin is inadequate for estimation of the effect of steroid treatment on the fetal hemolytic disease.
Materials and Methods
Samples of amniotic fluid from normal and Rhesussensitizedpregnant women were obtained during amniocentesis, performed under sterile conditions for various obstetri- 
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Samplesof amnioticfluid from a normal pregnancywere incubatedfor 24 h at 37#{176}C in the dark with bilirubinor the vehicle and 10 mol/L dexamethasone or prednisolone or a combination of bilirubin and a glucocorticoid. 
Results
The absorbance of amniotic fluid at 450 nm is known to represent unconjugated bilirubin. Table 1 Figure 1 also shows that addition of dexamethasone to a bilirubin-free amniotic fluid had no effect on the absorbance pattern in the wavelength range tested. Table 2 further shows the effect of two potent glucocorticoids on the height of the bilirubin peak. In this set of experiments the absorbance at 450 urn of 20 amniotic fluid samples was assayed spectrophotometrically 0, 1, 3, and 24 h after glucocorticoids were added. The presence of 10 Mmol of dexamethasone or prednisolone per liter caused a decrease in the measured absorbance, an effect that increases with the duration of incubation with the amniotic fluid, being maximal and statistically significant at 24 h of incubation. In other experiments (not shown) the magnitude of the decrease in absorbance was seen to be independent of the concentration of dexamethasone or prednisolone in the range of 1 to 100 mol/L, while a 0.1 imolJL concentration of the steroids produced only a small decrease in absorbance. At 0.01 .tmol/L, dexamethasone or prednisolone had no effect on the light absorption.
The diminished absorbance at 450 nm in the presence of high dexamethasone or prednisolone concentrations does not reflect a true decrease in bilirubin: incubation of the amniotic fluids with these glucocorticoids for 24 h did not affect the apparent concentration of bilirubin as determined by the chemical (diazo) method (Table 3) , nor did it affect the shape of the absorption spectrum of the diazo products.
In other experiments (results not shown) we noted that 10 .tmol of dexamethasone per liter had no effect on the electrophoretic determination of the US ratio of amniotic Absorbanceof normal amniotic fluids, to which 3.42 mol of bilirubin was added per liter, was measured at 450 nm against the same, bilirubin-free amnioticfluids. Dexamethasoneor prednisoloneto a final concentrationof 10 tmol/L were added and readings were done at the indicated times after addition of the steroids. Results are mean absorbancevalues ± SEM for 20 controls, 20 dexamethasone-containing samples, and five prednisolone-contaming samples. Controls contained the vehicle alone.
Signiflcanttydifferentfrom glucocorticoid-freecontrol values. p < 0.01. "Significantly differentfrom glucocorticoid-freecontrol values, p < 0.001. fluids. Dexamethasone did not affect this ratio in the "immatore" or "borderline" standard marker mixtures that are commercially available for the electrophoretic determination of US ratios in amniotic fluid.
One possiblemechanism of the steroid-induced decrease in absorption of amniotic fluid bilirubin is steroid-dependent displacement of the pigment from its bindingsites on some protein(s) in the amniotic fluid. However, as shown in Table   4 , the glucocorticoids also decrease the light absorption of bilirubin in albumin solution,in the absence of amniotic fluid, indicating that the effect does not depend on the presence ofsome specific component of the amniotic fluid.
A second plausible mechanism is formation of a colloid suspension of the pigment, a condition known to coincide with a reduction in light absorption (13). The steroids could favor the formation of a colloidal sol as a result of bilirubin supersaturation.
Because colloid formation increases the light scattering (14, 15) , we followed the light scattering of different concentrations of bilirubin in amniotic fluid in the absence and presence of dexamethasone. The results (Table   5) larly noted with bilirubin dissolved in 1 gIL solutions of albumin instead of amniotic fluid, and with bilirubin solutions incubated for only 5 mm or 1 h with the steroid (results not shown).
Discussion
Spectrophotometry of amniotic fluid bilirubin at 450 nm is quenched by the presence of the glucocorticoids dexamethasone and prednisolone, either of which decreases the height of the absorbance peak of bilirubin at 450 nm. The main significance of our findings is the potential for error: if the spectrophotometric bilirubin measurement is subject to error owing to the direct effect of glucocorticoid in the concentration present at the time the sample is drawn, then it would be of no value in many Rh-isoimmunization patients treated with glucocorticoids. In these cases the severity of the hemolytic disease may be grossly underestimated.
The glucocorticoid-induced decline in absorbance might also interfere with accurate determination of fetal maturity in normal pregnancies when the mother is receiving glucocorticoid hormones. These findings suggest that the previously reported decrease of bilirubin after administration of glucocorticoids is falsely exaggerated, and that extreme caution should be exercised in the interpretation of the direct spectrophotometricmeasurement in cases where glucocorticoid is being administered.
Interestingly, previous studies showed that although glucocorticoid treatment altered the bilirubin content as measured spectrophotometrically in amniotic fluid, it did not affect the lecithinisphingomyelin ratio (8). Furthermore, unexplained differences were reported between results of spectrophotometry, US ratio, and outcome of pregnancies in cases of Rh-isoimmunization treated with glucocorticoids (8, 9). Possibly dexamethasone produces a decrease in absorbance without improving the hemolytic disease of the fetus. This possibility is supported by the finding that the rapid decrease in amniotic fluid bilirubin also occurs in Rh-negative fetuses after therapy with betaniethasone (8). In addition, betamethasone administration did not produce prenatal evidence of improvement in fetal pulmonary maturity (8). Concordantly, we find no direct effect of the glucocorticoid on the chromatographic determination of the phospholipid ratio.
On the basis of the present observations we support the suggestion of Caritis et al. (8) that management of the Rhsensitized pregnancy be based on absorbance values obmined before steroid therapy and that the effect of steroid on the US ratio for prediction of the fetal condition after glucocorticoid administration needs to be established.Because our studies demonstrate that glucocorticoids do not affect the chemical determination of bilirubin, the chemical evaluation is superior to spectrophotometry for fluids obmined from glucocorticoid-treated patients.
The mechanism of the effect of glucocorticoids on the direct spectrophotometric determination of bilirubin remains to be elucidated.
We find that it is unlikely to be due to a displacement of bilirubin from binding sites on some specific components in the amniotic fluid, because the effect can also be reproduced with bilirubin dissolved in albumin solution ( Table 4) . Albumin is the major protein in amniotic fluid (16) and suspensions of bilirubin and albumin duplicate the absorbance peak seen in the amniotic fluid at 450 tim (6); the steroid could potentially displace the pigment from albumin. However, we didnot observe a difference in absorbance at 450 nm between bilirubin alone or in the presence of albumin.
Another possible explanation-that the steroids produce supersaturation and thereby enhance aggregation of the pigment with a resulting decrease in absorbance (13-15)-- was denied by the lack of a significant effect of the steroids on thelight scattering of biirubin solutions.
A third possibility, that theglucocorticoids enhance the rate of degradation of bilirubin in amniotic fluid, is supported by the finding that the decrease in absorbance is proportional to the incubation interval. However, the effect is also noted in albumin solutions, and the pigment concentration as determined by the chemical (diazo) method is not affected by the steroids (Table 3) , so this explanation should also be abandoned. Future studies are needed to clarify the mechanism of the effect.
